Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleImaging

Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study

Jonathan T. Unkart and Anne M. Wallace
Journal of Nuclear Medicine Technology September 2017, 45 (3) 181-184; DOI: https://doi.org/10.2967/jnmt.117.194415
Jonathan T. Unkart
Department of Surgery, Moores Cancer Center, University of California–San Diego, La Jolla, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Wallace
Department of Surgery, Moores Cancer Center, University of California–San Diego, La Jolla, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

99mTc-tilmanocept received recent Food and Drug Administration approval for lymphatic mapping in 2013. However, to our knowledge, no prior studies have evaluated the use of 99mTc-tilmanocept as a single agent in sentinel lymph node (SLN) biopsy in breast cancer. Methods: We executed this retrospective pilot study to assess the ability of 99mTc-tilmanocept to identify sentinel nodes as a single agent in clinically node-negative breast cancer patients. Patients received a single intradermal injection overlying the tumor of either 18.5 MBq (0.5 mCi) of 99mTc-tilmanocept on the day of surgery or 74.0 MBq (2.0 mCi) on the day before surgery by a radiologist. Immediate 3-view lymphoscintigraphy was performed. Intraoperatively, SLNs were identified with a portable γ-probe. A node was classified as hot if the count (per second) of the node was more than 3 times the background count. Descriptive statistics are reported. Results: Nineteen patients underwent SLN biopsy with single-agent 99mTc-tilmanocept. Immediate lymphoscintigraphy identified at least 1 sentinel node in 13 of 17 patients (76.5%). Intraoperatively, at least 1 (mean, 1.7 ± 0.8; range, 1–3) hot node was identified in all patients. Three patients (15.8%) had 1 disease-positive SLN. Conclusion: In this small, retrospective pilot study, 99mTc-tilmanocept performed well as a single agent for intraoperative sentinel node identification in breast cancer. A larger, randomized clinical trial is warranted to compare 99mTc-tilmanocept as a single agent with other radiopharmaceuticals for sentinel node identification in breast cancer.

  • tilmanocept
  • sentinel node biopsy
  • lymphatic mapping
  • breast cancer

Sentinel lymph node (SLN) biopsy is the standard of care for axillary staging in early-stage clinically node-negative breast cancer patients. Numerous lymphatic mapping agents of various strengths and with various limitations are commercially available to surgeons. In addition to the numerous dyes available (e.g., isosulfan blue, methylene blue, and indocyanine green), the radiopharmaceutical 99mTc-sulfur colloid has been used in the United States to validate the technique of SLN biopsy in breast cancer (1). However, in 2013 a newer agent, 99mTc-tilmanocept, received Food and Drug Administration approval for lymphatic mapping in breast cancer.

99mTc-tilmanocept, a small, receptor-targeted lymphatic mapping agent with demonstrated technical success in numerous tumor types (2–5), accumulates in SLNs by binding to the CD206 receptor residing on the surface of lymph node macrophages and dendritic cells (6). The agent consists of multiple units of diethylenetriaminepentaacetic acid and mannose, each covalently linked to a dextran backbone (7,8). Mannose binds the CD206 receptor, and the diethylenetriaminepentaacetic acid moieties serve as the binding site for 99mTc (6–8). 99mTc-tilmanocept is a macromolecule with an average diameter of 7 nm (7,8). This size differs significantly from that of the other radiopharmaceutical used in the United States for lymphatic mapping—99mTc-sulfur colloid—whose filtered particles vary in size between 100 and 220 nm (9). Regarding the sizes of radiopharmaceuticals used outside the United States, 99mTc-nanocolloid human serum albumin ranges from 5 to 100 nm and 99mTc-antimony trisulfide particles range from 3 to 30 nm (9).

Although axillary SLN biopsy is typically performed with 2 agents (radiopharmaceutical and blue dye) (10) to increase SLN identification, numerous studies have found that SLN biopsy with radiotracer alone is successful, thus questioning the utility of blue dye (10–13). To our knowledge, no prior studies have investigated the use of 99mTc-tilmanocept as a single agent for SLN biopsy in breast cancer. Thus, we executed this retrospective pilot study to evaluate the technical outcome of the use of 99mTc-tilmanocept as a single agent in breast cancer.

MATERIALS AND METHODS

We queried our prospectively maintained, Institutional Review Board–approved SLN database to identity patients undergoing single-agent lymphatic mapping and SLN biopsy with 99mTc-tilmanocept. The Institutional Review Board granted a waiver of consent for this retrospective review. After Food and Drug Administration approval in March 2013, 99mTc-tilmanocept was added to our institutional radiopharmacy formulary and became the routinely ordered radiopharmaceutical for sentinel node imaging in breast cancer. Patients with previous axillary surgery or known node-positive disease, or who were undergoing lymphatic mapping with 2 or more agents, were excluded from this analysis.

Radiopharmaceutical Preparation

99mTc-tilmanocept was prepared and quality control performed by a local central radiopharmacy (Cardinal Health) per the instructions on the package insert (Navidea Biopharmaceuticals, Inc.). Radiolabeling was performed offsite at Cardinal Health, and the agent was delivered during 1 of 3 delivery time-windows based on the timing of the scheduled injection. The agent was delivered in a single, 27-gauge tuberculin syringe to the Nuclear Medicine Department of the hospital. On arrival and immediately before injection, the agent was routinely surveyed for radioactivity by trained nuclear medicine technicians using a Capintec CRC-25R dose calibrator.

Injection Protocol

Injections were performed or supervised by 1 of 3 licensed radiologists. Per protocol, after confirming that the patient and injection-side were correct and positioning the patient supine, the radiologist used an alcohol wipe to clean the patient’s skin overlying the tumor, relying on the prior biopsy scar and patient confirmation to determine the location of the tumor. Patients in the 1-d protocol received a single intradermal 0.1-mL injection of 99mTc-tilmanocept (∼18.5 MBq [0.5 mCi]; mean ± SD, 19.6 ± 0.74 MBq [0.53 ± 0.02 mCi]) approximately 2–3 h before surgery. Patients in the 2-d protocol received a single intradermal 0.1-mL injection (∼74.0 MBq [2.0 mCi]; mean ± SD, 76.2 ± 2.96 MBq [2.06 ± 0.08 mCi]) approximately 15–20 h before surgery. A skin wheal confirmed the success of the injection. Residual radioactivity within the syringe was not routinely surveyed.

Lymphoscintigraphy

Images were obtained with a Philips (ADAC) Forte γ-camera, with a 20% energy window and a low-energy general purpose collimator. Images were acquired for 180 s, and 3 views were typically obtained (anterior, oblique, and lateral). The acquisition typically began 5 min after injection. However, if a patient was summoned immediately to the operative area, lymphoscintigraphy was not performed.

Surgery

Operations were performed by an experienced surgical oncologist who had more than 15 y of experience with SLN biopsies. Intraoperatively, background radioactivity levels were measured using a handheld intraoperative probe (Neoprobe) (programmed to read out in counts per second). For a node to qualify as hot, its intraoperative count had to exceed the background count (using either one 10-s count or the average of three 2-s counts, with the background measured directly on the patient ∼20 cm from the primary site) plus 3 times the SD of the background.

Removed lymph nodes were submitted to the Pathology Department for either frozen sectioning or permanent histopathologic staining. Frozen sections are typically obtained within 1 h of lymph node removal, and a positive result may warrant a patient’s immediately undergoing axillary lymph node dissection, depending on the clinical scenario. Permanent-section results are typically finalized by 5–7 d after surgery.

Statistical Methods

We report on baseline patient and technical characteristics. Descriptive statistics were calculated using R (https://www.r-project.org, version 3.1.2).

RESULTS

From May 2013 to July 2016, a total of 19 patients underwent SLN biopsy after single-agent injection with 99mTc-tilmanocept. Patient characteristics are summarized in Table 1. In brief, most patients had breast-conserving surgery (84.2%), T1/T2-sized tumors (78.9%), and hormone receptor–positive tumors (89.5%). Additionally, most patients (78.9%) underwent the 2-d protocol. Of the patients who underwent immediate imaging with lymphoscintigraphy, 76.5% had at least 1 visualized node. Two patients did not undergo lymphoscintigraphy because they were summoned to the operative area before imaging could be completed.

View this table:
  • View inline
  • View popup
TABLE 1

Patient Characteristics

At least 1 intraoperative SLN was identified in each patient. In total, 32 radioactive nodes were detected and removed (mean ± SD, 1.7 ± 0.75; range, 1–3). Three patients (15.8%) had 1 identified node that was positive for disease. Of the 3 patients with disease-positive sentinel nodes, 2 underwent axillary lymph node dissection as part of their treatment pathway. In these 2 patients, no other disease was found in the completion axillary-lymph-node-dissection specimens (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

Findings in the 3 Patients with Disease-Positive SLNs

DISCUSSION

In this retrospective pilot study, 99mTc-tilmanocept performed well as a single agent for sentinel node biopsy in early breast cancer. Intraoperatively, at least 1 SLN was identified in each patient. 99mTc-tilmanocept identified 3 nodes with pathologically proven disease in 3 patients. For the 2 patients who had completion axillary-lymph-node dissections, no further disease was found. Furthermore, patients for whom no node was identified on immediate lymphoscintigraphy still had a node identified intraoperatively with a γ-probe. Additionally, 99mTc-tilmanocept offered flexibility in patient scheduling, as SLN biopsy was successful both in patients receiving the injection on the day of surgery and in patients receiving it on the day before surgery.

In March 2013, 99mTc-tilmanocept received initial Food and Drug Administration approval for lymphatic mapping in breast cancer and melanoma. To our knowledge, no prior trial or study has evaluated the performance of 99mTc-tilmanocept as a single agent for intraoperative lymphatic mapping in breast cancer. The initial clinical trials validating the use of 99mTc-tilmanocept in breast cancer and melanoma involved comparisons and measurements of concordance with blue dye (3,5,14). Although the data from these trials showed the performance of 99mTc-tilmanocept to be consistent and reliable, the use of blue dye may have assisted with identification of the hot lymph nodes. In a different disease process, oral squamous cell carcinoma of the head and neck, the use of 99mTc-tilmanocept as a single agent identified at least 1 SLN in 97.6% of patients (4). Preliminary results from our pilot study demonstrate excellent performance for intraoperative SLN identification in breast cancer when 99mTc-tilmanocept is used as the lone injected agent.

99mTc-tilmanocept exhibits radiopharmaceutical properties ideal for SLN procedures. Ideal agents for mapping lymph nodes will clear the injection site rapidly, show rapid and sustained uptake within the sentinel node, and show low uptake within distal lymph nodes (15). In prior work, 99mTc-tilmanocept cleared the injection site more rapidly than 99mTc-sulfur colloid (16). When an agent is used alone, this trait is highly desirable as some surgeons prefer to inject the radiopharmaceutical intraoperatively (12). At our institution, patients are required to receive the injection while awake in the Nuclear Medicine Department by a licensed individual, and we have found that 99mTc-tilmanocept caused significantly less injection site pain than filtered 99mTc-sulfur colloid (17).

This study was not without a few limitations. First, the sample size, although sufficient to draw conclusions about the small subset of patients at our institution, would be bolstered by being larger. A larger, randomized, controlled study could provide more conclusive results and data about the use of 99mTc-tilmanocept as a single agent in breast cancer. Furthermore, a true false-negative rate could not be determined because axillary lymph node dissection is no longer the accepted standard of care in all breast cancer patients. However, in the 2 patients who underwent completion axillary dissection, it was found that 99mTc-tilmanocept had identified the only disease-positive lymph nodes. Lastly, as is the case for all retrospective studies, the results might have been biased by unknown confounding variables.

CONCLUSION

In this small, retrospective study, 99mTc-tilmanocept performed well as a single agent in sentinel node identification in breast cancer. A larger, randomized clinical trial is warranted to compare 99mTc-tilmanocept as a single agent with other radiopharmaceuticals for sentinel node identification in breast cancer.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Jul. 13, 2017.

REFERENCES

  1. 1.↵
    1. Krag DN,
    2. Weaver DL,
    3. Alex JC,
    4. Fairbank JT
    . Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–339.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Surasi DS,
    2. O’Malley J,
    3. Bhambhvani P
    . 99mTc-tilmanocept: a novel molecular agent for lymphatic mapping and sentinel lymph node localization. J Nucl Med Technol. 2015;43:87–91.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Wallace AM,
    2. Han LK,
    3. Povoski SP,
    4. et al
    . Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013;20:2590–2599.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Agrawal A,
    2. Civantos FJ,
    3. Brumund KT,
    4. et al
    . [99mTc]tilmanocept accurately detects sentinel lymph nodes and predicts node pathology status in patients with oral squamous cell carcinoma of the head and neck: results of a phase III multi-institutional trial. Ann Surg Oncol. 2015;22:3708–3715.
    OpenUrl
  5. 5.↵
    1. Sondak VK,
    2. King DW,
    3. Zager JS,
    4. et al
    . Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680–688.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Azad AK,
    2. Rajaram MV,
    3. Metz WL,
    4. et al
    . Gamma-tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). J Immunol. 2015;195:2019–2029.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Vera DR,
    2. Wallace AM,
    3. Hoh CK
    . [99mTc]MAG3-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection. Nucl Med Biol. 2001;28:493–498.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Vera DR,
    2. Wallace AM,
    3. Hoh CK,
    4. Mattrey RF
    . A synthetic macromolecule for sentinel node detection: 99mTc-DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951–959.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Giammarile F,
    2. Alazraki N,
    3. Aarsvold JN,
    4. et al
    . The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40:1932–1947.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. He PS,
    2. Li F,
    3. Li GH,
    4. Guo C,
    5. Chen TJ
    . The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review. BMC Cancer. 2016;16:107.
    OpenUrl
  11. 11.
    1. O’Reilly EA,
    2. Prichard RS,
    3. Al Azawi D,
    4. et al
    . The value of isosulfan blue dye in addition to isotope scanning in the identification of the sentinel lymph node in breast cancer patients with a positive lymphoscintigraphy: a randomized controlled trial (ISRCTN98849733). Ann Surg. 2015;262:243–248.
    OpenUrl
  12. 12.↵
    1. Johnson CB,
    2. Boneti C,
    3. Korourian S,
    4. Adkins L,
    5. Klimberg VS
    . Intraoperative injection of subareolar or dermal radioisotope results in predictable identification of sentinel lymph nodes in breast cancer. Ann Surg. 2011;254:612–618.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Kang T,
    2. Yi M,
    3. Hunt KK,
    4. et al
    . Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010;17(suppl 3):280–285.
    OpenUrl
  14. 14.↵
    1. Leong SP,
    2. Kim J,
    3. Ross M,
    4. et al
    . A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961–969.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Wallace AM,
    2. Hoh CK,
    3. Vera DR,
    4. Darrah DD,
    5. Schulteis G
    . Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531–538.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Wallace AM,
    2. Hoh CK,
    3. Ellner SJ,
    4. Darrah DD,
    5. Schulteis G,
    6. Vera DR
    . Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913–921.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Unkart JT,
    2. Baker JL,
    3. Hosseini A,
    4. et al
    . Comparison of post-injection site pain between technetium sulfur colloid and technetium tilmanocept in breast cancer patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2015;22(suppl 3):S559–S565.
    OpenUrl
  • Received for publication April 7, 2017.
  • Accepted for publication June 1, 2017.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 45 (3)
Journal of Nuclear Medicine Technology
Vol. 45, Issue 3
September 1, 2017
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study
Jonathan T. Unkart, Anne M. Wallace
Journal of Nuclear Medicine Technology Sep 2017, 45 (3) 181-184; DOI: 10.2967/jnmt.117.194415

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study
Jonathan T. Unkart, Anne M. Wallace
Journal of Nuclear Medicine Technology Sep 2017, 45 (3) 181-184; DOI: 10.2967/jnmt.117.194415
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Early 10-Minute Postinjection [18F]F-FAPI-42 uEXPLORER Total-Body PET/CT Scanning Protocol for Staging Lung Cancer Using HYPER Iterative Reconstruction
  • Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99mTc-Pyrophosphate
  • Does Arthrography Improve Accuracy of SPECT/CT for Diagnosis of Aseptic Loosening in Patients with Painful Knee Arthroplasty: A Systematic Review and Metaanalysis
Show more Imaging

Similar Articles

Keywords

  • Tilmanocept
  • sentinel node biopsy
  • lymphatic mapping
  • breast cancer
SNMMI

© 2025 SNMMI

Powered by HighWire